Trial NCT04600336

Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer

This phase II trial compares the effect of oxybutynin versus placebo for reducing hot flashes
in men receiving androgen deprivation (hormone) therapy for the treatment of prostate cancer
. Androgen deprivation therapy decreases testosterone and other androgens through medications
or surgical removal of the testicles. Relative to placebo, low- or high-dose oxybutynin may
reduce hot flashes in men receiving androgen deprivation therapy.


Oxybutynin Chloride, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration


Prostate Carcinoma


Bradley J. Stish, MD, Joshua Lukenbill, Priyank P. Patel, Bryan A. Faller, Debra M. Prow, Katie S. Murray, Jay W. Carlson, Ralph J. Hauke, Christopher H. Chay, Samer S. Kasbari, Grant R. Seeger, Harish G. Ahuja, Anterpreet S. Neki, Tareq Al Baghdadi, Daniel M. Anderson, Preston D. Steen, Dayssy A. Diaz Pardo, Brandon Mullins, Elizabeth M. Gore, Timothy R. Wassenaar, Bradley J. Stish, Jones T. Nauseef, Justin Famoso, Richard L. Deming, Edward P. Gelmann, Erica D. Lovett Fournier, Ashley Springer, John C. Henegan, Neha R. Chawla, Benjamin A. Gartrell, Ranveer Nand

See list of participating sites